Here are the DEF 14A proxy statements from Tivic Health Systems, Inc. (TIVC) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow TIVC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TIVC filings page.
Valion Bio, Inc. is asking stockholders to vote at a fully virtual 2026 annual meeting on May 28, 2026. Holders of common stock as of April 24, 2026, when 3,139,095 shares were outstanding, may vote; holders of Series A, B and C preferred cannot.
Proposals include re-electing one Class II director, expanding the 2021 Equity Incentive Plan by 2,581,608 shares to a total of 3,219,566 authorized shares, and ratifying Rosenberg Rich Baker Berman, P.A. as auditor. Several items seek Nasdaq Listing Rule 5635(d) approval for issuing common stock upon conversion of Series B and Series C preferred, a senior secured convertible note, related warrants, and a common stock Equity Line of Credit with Tumim Stone Capital, LLC.
Tivic Health Systems is calling a virtual special stockholder meeting on February 19, 2026 to vote on four proposals tied to recent financings. Stockholders are being asked to approve, under Nasdaq Listing Rule 5635(d), large potential issuances of common stock upon conversion of Series C preferred stock and related warrants, a senior secured convertible note and warrant held by 3i, and Series B preferred stock and related warrants now held by 3i. As of December 29, 2025, Tivic had 2,525,778 common shares outstanding.
The Series C financing could allow issuance of up to 207,692,305 common shares on conversion of Series C preferred, plus 90,135,297 shares on warrant exercise, which the company states would dilute current holders’ ownership to about 0.59%. The Note could convert into up to 52,093,421 shares at the floor price, plus 4,553,213 warrant shares, and the amended Series B structure lowers the conversion floor to $0.39, increasing potential share issuance. A fourth proposal would permit adjournment of the meeting to solicit more votes. The board unanimously recommends voting “FOR” all proposals.